{"analyses":[{"ciLowerLimit":"-40.89","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"147.60","groupDescription":"Sedentary Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.8260","paramType":"Difference in LS Mean","paramValue":"53.36","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-132.94","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"57.14","groupDescription":"Sedentary Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.2540","paramType":"Difference in LS Mean","paramValue":"-37.9","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-101.63","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"97.73","groupDescription":"Sedentary Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.4870","paramType":"Difference in LS Mean","paramValue":"-1.95","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"0.07","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"75.46","groupDescription":"Non-Sedentary Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.0497","paramType":"Difference in LS Mean","paramValue":"37.76","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-42.94","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"34.22","groupDescription":"Non-Sedentary Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.5745","paramType":"Difference in LS Mean","paramValue":"-4.36","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"10.62","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"89.08","groupDescription":"Non-Sedentary Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.0189","paramType":"Difference in LS Mean","paramValue":"49.85","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-4.00","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"21.03","groupDescription":"Moderate to Vigorous Physical Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.1302","paramType":"Difference in LS Mean","paramValue":"8.51","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-8.18","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"17.16","groupDescription":"Moderate to Vigorous Physical Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.2780","paramType":"Difference in LS Mean","paramValue":"4.49","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-5.01","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"21.23","groupDescription":"Moderate to Vigorous Physical Activity Time: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.1529","paramType":"Difference in LS Mean","paramValue":"8.11","statisticalMethod":"MMRM analysis; 1-sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-72.77","upperLimit":"69.92","value":"-1.42"},{"groupId":"OG001","lowerLimit":"-9.88","upperLimit":"113.75","value":"51.93"},{"groupId":"OG002","lowerLimit":"-101.94","upperLimit":"23.29","value":"-39.33"},{"groupId":"OG003","lowerLimit":"-72.89","upperLimit":"66.14","value":"-3.37"}]}],"title":"Time for Sedentary Activity"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-66.14","upperLimit":"-9.32","value":"-37.73"},{"groupId":"OG001","lowerLimit":"-24.88","upperLimit":"24.95","value":"0.03"},{"groupId":"OG002","lowerLimit":"-67.63","upperLimit":"-16.56","value":"-42.09"},{"groupId":"OG003","lowerLimit":"-14.87","upperLimit":"39.10","value":"12.11"}]}],"title":"Time for Non-Sedentary Physical Activity"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-13.91","upperLimit":"5.02","value":"-4.45"},{"groupId":"OG001","lowerLimit":"-4.18","upperLimit":"12.32","value":"4.07"},{"groupId":"OG002","lowerLimit":"-8.29","upperLimit":"8.39","value":"0.05"},{"groupId":"OG003","lowerLimit":"-5.37","upperLimit":"12.71","value":"3.67"}]}],"title":"Time for Moderate to Vigorous Physical Activity"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"13"}],"units":"Participants"}],"description":"Physical activity was monitored using accelerometry (wearable digital sensors). Physical activity was categorized as: sedentary activity, non-sedentary physical activity, and moderate to vigorous physical activity. In this outcome measure time for each type of physical activity per day was considered. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using mixed models repeated measures (MMRM) model.","dispersionType":"90% Confidence Interval","groups":[{"description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses).","id":"OG000","title":"Part A: Placebo"},{"description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG001","title":"Part A: Ponsegromab 100 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG002","title":"Part A: Ponsegromab 200 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG003","title":"Part A: Ponsegromab 400 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Censored analysis set:all evaluable participants.For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed'' =participants evaluable for this outcome measure at Week 12.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12","title":"Part A: Change From Baseline in Physical Activity at Week 12","type":"SECONDARY","unitOfMeasure":"Minutes per day"}